Clinical Trial News and Research

RSS

Achillion second-quarter net loss increases to $6.4 million

Achillion Pharmaceuticals, Inc., a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and six months ended June 30, 2010. For the second quarter of 2010, the Company reported a net loss of $6.4 million, compared with a net loss of $6.1 million for the same period last year. Cash, cash equivalents and marketable securities as of June 30, 2010 were $19.5 million.

13 Aug 2010

Hana Biosciences second-quarter net loss decreases to $6.3 million

Hana Biosciences Inc., a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the three and six months ended June 30, 2010, and provided a corporate update.

13 Aug 2010

NewCardio second-quarter net loss decreases to $1.5 million

NewCardio, Inc., a cardiac diagnostic technology provider, today announced financial results for the second quarter ended June 30, 2010.

13 Aug 2010

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.

13 Aug 2010

NovaBay second-quarter net loss increases to $1.2 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported second quarter financial results and highlighted the clinical progress of its in-house programs.

13 Aug 2010

CPF urges people to consider clinical trials for pulmonary fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is urging the more than 128,000 people known to suffer from the deadly lung disease, pulmonary fibrosis (PF), to consider clinical trials, including two new ones funded by the National Institutes of Health (NIH). Clinical trials of potential drug therapies are critical to the discovery of treatments for any disease and for a disease like PF that claims as many lives each year as breast cancer with virtually no survivors, they are the likely path to answers and saved lives.

13 Aug 2010

Study examines impact of microvascular decompression surgery for type 2 diabetes

A team of Allegheny General Hospital (AGH) physicians led by neurosurgical pioneer Peter Jannetta, MD, has made an important new discovery linking the central nervous system to the onset and progression of type 2 diabetes mellitus.Reporting today in the journal Surgical Neurology International, Dr. Jannetta and his colleagues present evidence from a prospective clinical trial that vascular compression of a section of the brain called the medulla oblongata is a factor in some patients with type 2 diabetes and that microvascular decompression surgery (MVD) may be an effective treatment for the condition.

13 Aug 2010

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).

13 Aug 2010

VirtualScopics second-quarter revenues increase 27% to $3.22 million

VirtualScopics, Inc., a leading provider of quantitative imaging for clinical trials, today reported revenues of $3,221,593 for the second quarter of 2010 compared to revenues of $2,541,316 in the second quarter of 2009, a 27% increase. Excluding work performed in 2009 for the Department of Defense under projects that ended in 2009, the company posted a 34% increase in second quarter 2010 revenues as compared to the second quarter of 2009 and a 45% increase in revenues during the first half of 2010 compared to the first half of 2009.

12 Aug 2010

Genta reports second-quarter net income of $25.4M against net loss of $43.1M in 2009

Genta Incorporated today announced financial results for the quarter ending June 30, 2010.

12 Aug 2010

Labopharm second-quarter total revenue increases to $6.8 million

Labopharm Inc. today reported its financial results for the second quarter and first six months ended June 30, 2010. All figures are in Canadian dollars unless otherwise stated.

12 Aug 2010

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.

12 Aug 2010

Medical International Technology reports on progress in China

Medical International Technology Inc. is pleased to announce its progress in China.

12 Aug 2010

Tengion announces clinical, corporate and second-quarter financial updates

Tengion Inc. today provided a corporate and product development update and reported its financial results for the quarter ended June 30, 2010.

12 Aug 2010

Study shows change in training can reduce ACL tears in female athletes

Anterior cruciate ligament injuries are a common and debilitating problem, especially for female athletes. A new study from UC Davis shows that changes in training can reduce shear forces on knee joints and could help cut the risk of developing ACL tears. The research was published online Aug. 3 in the Journal of Biomechanics.

12 Aug 2010

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Temasek Life Science Ventures Pte Ltd and Emergent BioSolutions Inc. today announced their agreement to form EPIC BIO Pte Ltd, a joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.

12 Aug 2010

Isotechnika second-quarter revenue from continuing operations increases to $1.49 million

Isotechnika Pharma Inc. today announced financial results for the second quarter ended June 30, 2010.

12 Aug 2010

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.

11 Aug 2010

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has successfully completed a Phase 1B/2 dose-ranging clinical study with PMX-60056, a synthetic small-molecule designed to reverse heparin and low molecular weight heparin anticoagulants.

11 Aug 2010

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today released financial results for the second quarter 2010, ended June 30, 2010.

11 Aug 2010

Clinical Trial News and Research

Achillion second-quarter net loss increases to $6.4 million

Hana Biosciences second-quarter net loss decreases to $6.3 million

NewCardio second-quarter net loss decreases to $1.5 million

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

NovaBay second-quarter net loss increases to $1.2 million

CPF urges people to consider clinical trials for pulmonary fibrosis

Study examines impact of microvascular decompression surgery for type 2 diabetes

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

VirtualScopics second-quarter revenues increase 27% to $3.22 million

Genta reports second-quarter net income of $25.4M against net loss of $43.1M in 2009

Labopharm second-quarter total revenue increases to $6.8 million

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

Medical International Technology reports on progress in China

Tengion announces clinical, corporate and second-quarter financial updates

Study shows change in training can reduce ACL tears in female athletes

TLV, Emergent BioSolutions form joint venture to develop broad spectrum pandemic flu vaccine

Isotechnika second-quarter revenue from continuing operations increases to $1.49 million

HemaQuest commences HQK-1004 global Phase 2 clinical trial in EBV-related malignancies

PolyMedix's PMX-60056 Phase 1B/2 dose-ranging clinical study for heparin reversal meets study endpoints

Protox reports $1.1M net income for second-quarter 2010 vs. $1.8M net loss for second-quarter 2009

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News